Navigation Links
Tibotec Pharmaceuticals a Respectful Partner to HIV Community in Pricing of Novel New HIV NNRTI, INTELENCE
Date:1/31/2008

WASHINGTON, Jan. 31 /PRNewswire/ -- The FDA approved Tibotec Pharmaceutical's novel non-nucleoside reverse transcriptase inhibitor (NNRTI) INTELENCE(R). The company also announced introductory pricing for the eagerly anticipated new compound at $21.80 per day, substantially lower than other recently introduced antiretrovirals.

"The efficacy that INTELENCE (TMC125/etravirine) has shown in the DUET studies is impressive. INTELENCE is an important new HIV medication that, for the first time, re-opens the NNRTI class to patients with NNRTI-resistant virus," stated Donna Christian-Chistensen, MD, Chair of the Congressional Black Caucus Health Brain Trust and TIICANN board member. "We applaud Tibotec for its efforts to make this innovative new medication available and accessible to people living with HIV."

In the Duet study, 612 patients were randomized and treated (304 in the TMC125 group, 308 in the placebo group). At week 24, 170 (56%) patients in the TMC125 group and 119 (39%) patients in the placebo group achieved a confirmed viral load of less than 50 copies per mL (difference in response rates 17%; 95% CI 9-25; p=0 005). Most adverse events were mild or moderate in severity. The type and incidence of adverse events, including neuropsychiatric events, seen with TMC125 were generally comparable with placebo, with the exception of rash (61 [20%] patients on TMC125 vs 30 [10%] on placebo) and diarrhea (36 [12%] patients on TMC125 vs 63 [20%] on placebo).

"As a long time member of the Fair Price Coalition, I must recognize the transparency, understanding and respect exhibited by Tibotec in its relations with the HIV/AIDS community," said Bill Arnold, Executive Director of TIICANN. "It is remarkable that Tibotec remains collegial in the broadest sense of that word in the face of the challenges being faced by its parent company, Johnson & Johnson."

"As a patient with a remarkably low tolerance for most antiretrovirals, I have always depended on NNRTIs as the base of my regimens," admitted Gary Rose, TIICANN's Chair. "It is a major relief for me to have a new option as my present regimen combining an NNRTI and a protease inhibitor which is both toxic and weakening. I think this is quite a common phenomena among patients with long-term exposure to antiretrovirals and so Tibotec's determination to develop new, non-cross resistant drugs for HIV, and just as importantly, oral compounds for hepatitis C - the company's dedication to virology is notable - is a cause for quiet celebration among infectious disease doctors and my fellow patients."

Congressman Maurice Hinchey, a TII CANN Board member stated: "Representing New York, which continues to bear the largest portion of the many burdens of the American AIDS epidemic, I'm very sensitive to any efforts to make new treatments affordable and accessible to all regardless of their financial circumstances or health insurance coverage. No HIV+ or AIDS patient should be denied access to critical drugs that can help them live longer and more productive lives."

Contact: Bill Arnold (202) 588-1775


'/>"/>
SOURCE The AIDS Institute
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Arena Pharmaceuticals to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
2. MAP Pharmaceuticals to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
3. Transcept Pharmaceuticals to Present at the 2008 Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
4. Amylin Pharmaceuticals Reports 2007 Financial Results
5. MiddleBrook Pharmaceuticals to Raise $21 Million Through Private Placement of Common Equity
6. Acura Pharmaceuticals, Inc. Announces Appointment of George K. Ross as Director
7. Wyeth and Teva Pharmaceuticals Extend the Standstill Period Relating to Tevas Launch of Generic Pantoprazole
8. Bradley Pharmaceuticals Announces Filing of Definitive Proxy Statement for Special Meeting of Stockholders to Approve Merger With Nycomed
9. MAP Pharmaceuticals Reaches Agreement with FDA on Special Protocol Assessment for MAP0004 Phase 3 Clinical Trial in Patients With Migraine
10. Access Licenses MuGard(TM) to RHEI Pharmaceuticals, a Leading Specialty Pharmaceutical Company for Distribution in China and Certain Other Southeast Asian Countries
11. Three Rivers Pharmaceuticals(R), LLC Acquires Hepatitis C Drug Infergen(R) from Valeant Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2016)... ... 28, 2016 , ... "Color Grading media can be time consuming but with ... media," said Christina Austin - CEO of Pixel Film Studios. , With the ... stylish color grades to their footage. A LUT is a Lookup Table that contains ...
(Date:5/28/2016)... , ... May 28, 2016 , ... In a part of the city where’s it’s ... new farm-to-table Kelowna restaurants is hoping to attract diners with a taste for ... Suites officially opened the doors to Cornerstone Grill, an urban casual restaurant focusing on ...
(Date:5/27/2016)... (PRWEB) , ... May 27, 2016 , ... Two director-level ... as YWCA Tribute to Women and Industry (TWIN) 2016 honorees. The award recognizes ... workplace. For this year, Geri Boone, Director of the MLTSS (Managed Long-Term Services and ...
(Date:5/27/2016)... ... May 27, 2016 , ... With over 60 percent of acute ... for a sustainable product to aid in the rehabilitation process has steadily increased. Ekso ... of individuals with hemiplegia due to stroke. , Ekso Bionics has now received clearance ...
(Date:5/27/2016)... ... May 27, 2016 , ... In response ... many who are unaware of the plight of aphasia. In collaboration with the ... “Stroke Awareness” campaign. , The link between stroke and aphasia is relatively unknown, ...
Breaking Medicine News(10 mins):
(Date:5/25/2016)... Texas , May 25, 2016 ... the issuance to it by the US Patent ... The company,s technology includes proprietary processes for electronic ... for health and wellness programs, HIPAA compliance and ... "Our technology ...
(Date:5/25/2016)... 25, 2016 ReportsnReports.com adds ... report that provides an overview on therapeutic pipeline ... various stages, therapeutics assessment by drug target, mechanism ... molecule type, along with latest updates, and featured ... players involved in the therapeutic development for Chronic ...
(Date:5/24/2016)... LONDON , May 24, 2016 ... erfüllt beide primären Endpunkte ... und Überlegenheit in ‚ausgezeichneter plus guter ... aufsteigenden Colons    ,      (Logo: ... B.V. gab heute neue positive Daten von der ...
Breaking Medicine Technology: